Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1829 1
1858 1
1900 1
1902 1
1907 1
1911 2
1913 1
1917 1
1920 1
1921 1
1923 2
1938 1
1943 1
1946 3
1947 1
1948 7
1949 12
1950 2
1951 6
1952 5
1953 5
1954 4
1955 5
1956 3
1957 6
1958 4
1959 2
1960 6
1961 6
1962 3
1963 6
1964 15
1965 9
1966 9
1967 7
1968 8
1969 8
1970 15
1971 6
1972 11
1973 12
1974 15
1975 15
1976 14
1977 13
1978 10
1979 19
1980 10
1981 16
1982 22
1983 18
1984 15
1985 24
1986 18
1987 13
1988 24
1989 17
1990 17
1991 24
1992 25
1993 16
1994 16
1995 18
1996 14
1997 14
1998 14
1999 15
2000 14
2001 11
2002 19
2003 15
2004 9
2005 20
2006 23
2007 23
2008 26
2009 23
2010 20
2011 29
2012 25
2013 23
2014 18
2015 31
2016 22
2017 25
2018 27
2019 28
2020 28
2021 25
2022 20
2023 16
2024 20
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,136 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, De Waele K, Farooqi IS, Gonneau-Lejeune J, Gordon G, Kohlsdorf K, Poitou C, Puder L, Swain J, Stewart M, Yuan G, Wabitsch M, Kühnen P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Clément K, et al. Among authors: gordon g. Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. doi: 10.1016/S2213-8587(20)30364-8. Epub 2020 Oct 30. Lancet Diabetes Endocrinol. 2020. PMID: 33137293 Clinical Trial.
Loss of endothelial CD2AP causes sex-dependent cerebrovascular dysfunction.
Vandal M, Institoris A, Reveret L, Korin B, Gunn C, Hirai S, Jiang Y, Lee S, Lee J, Bourassa P, Mishra RC, Peringod G, Arellano F, Belzil C, Tremblay C, Hashem M, Gorzo K, Elias E, Yao J, Meilandt B, Foreman O, Roose-Girma M, Shin S, Muruve D, Nicola W, Körbelin J, Dunn JF, Chen W, Park SK, Braun AP, Bennett DA, Gordon GRJ, Calon F, Shaw AS, Nguyen MD. Vandal M, et al. Among authors: gordon grj. Neuron. 2025 Mar 19;113(6):876-895.e11. doi: 10.1016/j.neuron.2025.01.006. Epub 2025 Jan 31. Neuron. 2025. PMID: 39892386
CD2AP at the junction of nephropathy and Alzheimer's disease.
Vandal M, Janmaleki M, Rea I, Gunn C, Hirai S, Biernaskie J, Chun J, Gordon G, Shaw A, Sanati-Nezhad A, Pfeffer G, Calon F, Nguyen MD. Vandal M, et al. Among authors: gordon g. Mol Neurodegener. 2025 Jun 4;20(1):63. doi: 10.1186/s13024-025-00852-x. Mol Neurodegener. 2025. PMID: 40462155 Free PMC article. Review.
Receptor models.
Gordon GE. Gordon GE. Environ Sci Technol. 1988 Oct;22(10):1132-42. doi: 10.1021/es00175a002. Environ Sci Technol. 1988. PMID: 22148602 No abstract available.
Management of gout.
Gordon GV, Schumacher HR. Gordon GV, et al. Am Fam Physician. 1979 Jan;19(1):91-7. Am Fam Physician. 1979. PMID: 760433
Nocardial meningitis: case reports and review.
Bross JE, Gordon G. Bross JE, et al. Among authors: gordon g. Rev Infect Dis. 1991 Jan-Feb;13(1):160-5. doi: 10.1093/clinids/12.5.160. Rev Infect Dis. 1991. PMID: 2017617 Review.
1,136 results